NASDAQ:MOLN Molecular Partners (MOLN) Stock Price, News & Analysis $3.82 +0.23 (+6.25%) Closing price 08/29/2025 02:17 PM EasternExtended Trading$3.78 -0.05 (-1.31%) As of 08/29/2025 04:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Molecular Partners Stock (NASDAQ:MOLN) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Molecular Partners alerts:Sign Up Key Stats Today's Range$3.60▼$3.7550-Day Range$3.51▼$4.2252-Week Range$3.36▼$7.60Volume4,139 shsAverage Volume4,219 shsMarket Capitalization$154.43 millionP/E RatioN/ADividend YieldN/APrice Target$12.00Consensus RatingStrong Buy Company Overview Molecular Partners AG, a clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein that is in Phase I clinical trial; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia. It also develops Switch-DARPin platform, a multispecific cKIT x CD16a x CD47 Switch-DARPin program for targeted and conditional immune cell activation; and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors. It has license and research collaboration agreements with Novartis Pharma AG to develop DARPin-conjugated radioligand therapies; and collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics. Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland. Read More Molecular Partners Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks34th Percentile Overall ScoreMOLN MarketRank™: Molecular Partners scored higher than 34% of companies evaluated by MarketBeat, and ranked 783rd out of 950 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.8 / 5Analyst RatingStrong Buy Consensus RatingMolecular Partners has received a consensus rating of Strong Buy. The company's average rating score is 3.50, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageMolecular Partners has received no research coverage in the past 90 days.Read more about Molecular Partners' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Molecular Partners are expected to decrease in the coming year, from ($1.93) to ($2.08) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Molecular Partners is -1.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Molecular Partners is -1.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMolecular Partners has a P/B Ratio of 1.20. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Molecular Partners' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted0.09% of the float of Molecular Partners has been sold short.Short Interest Ratio / Days to CoverMolecular Partners has a short interest ratio ("days to cover") of 16.6, which indicates bearish sentiment.Change versus previous monthShort interest in Molecular Partners has recently decreased by 3.08%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldMolecular Partners does not currently pay a dividend.Dividend GrowthMolecular Partners does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.09% of the float of Molecular Partners has been sold short.Short Interest Ratio / Days to CoverMolecular Partners has a short interest ratio ("days to cover") of 16.6, which indicates bearish sentiment.Change versus previous monthShort interest in Molecular Partners has recently decreased by 3.08%, indicating that investor sentiment is improving. News and Social Media2.4 / 5News Sentiment0.35 News SentimentMolecular Partners has a news sentiment score of 0.35. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 1.05 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 10 news articles for Molecular Partners this week, compared to 1 article on an average week.Search Interest1 people have searched for MOLN on MarketBeat in the last 30 days. MarketBeat FollowsOnly 1 people have added Molecular Partners to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Molecular Partners insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.93% of the stock of Molecular Partners is held by insiders.Percentage Held by InstitutionsOnly 26.55% of the stock of Molecular Partners is held by institutions.Read more about Molecular Partners' insider trading history. Receive MOLN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Molecular Partners and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. MOLN Stock News HeadlinesQ3 EPS Forecast for Molecular Partners Lifted by AnalystAugust 30 at 2:45 AM | americanbankingnews.comMolecular Partners reports financial results and highlights recent clinical pipeline progress for H1 2025August 25, 2025 | globenewswire.comWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was projected. According to Porter Stansberry, this is panic-level borrowing… and a clear sign we’re nearing America’s financial breaking point. In his latest emergency briefing, Porter outlines why the cracks in our system are widening fast—and how Trump’s policies may be accelerating the collapse. More importantly, he reveals three moves you can make now to protect and potentially grow your wealth before the levee breaks.August 30 at 2:00 AM | Porter & Company (Ad)Molecular Partners (MOLN) Projected to Post Quarterly Earnings on MondayAugust 23, 2025 | americanbankingnews.comMolecular Partners appoints Martin Steegmaier as chief scientific officerAugust 21, 2025 | msn.comMolecular Partners AG ADR MOLN (U.S.: Nasdaq) - The Wall Street JournalAugust 5, 2025 | wsj.comMolecular Partners AG News (MOLN) - Investing.comJuly 2, 2025 | investing.comMolecular Partners AG (MOLN) - Yahoo FinanceJune 26, 2025 | au.finance.yahoo.comSee More Headlines MOLN Stock Analysis - Frequently Asked Questions How have MOLN shares performed this year? Molecular Partners' stock was trading at $4.75 at the start of the year. Since then, MOLN stock has decreased by 19.5% and is now trading at $3.8250. How were Molecular Partners' earnings last quarter? Molecular Partners AG Sponsored ADR (NASDAQ:MOLN) issued its quarterly earnings data on Monday, August, 25th. The company reported ($0.67) EPS for the quarter, missing the consensus estimate of ($0.53) by $0.14. When did Molecular Partners IPO? Molecular Partners (MOLN) raised $81 million in an initial public offering (IPO) on Wednesday, June 16th 2021. The company issued 3,000,000 shares at $27.14 per share. J.P. Morgan, SVB Leerink, Cowen and RBC Capital Markets served as the underwriters for the IPO and Kempen & Co. was co-manager. How do I buy shares of Molecular Partners? Shares of MOLN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Molecular Partners own? Based on aggregate information from My MarketBeat watchlists, some other companies that Molecular Partners investors own include PayPal (PYPL), Pfizer (PFE), NVIDIA (NVDA), Advanced Micro Devices (AMD), Robinhood Markets (HOOD), Taiwan Semiconductor Manufacturing (TSM) and Adobe (ADBE). Company Calendar Last Earnings8/25/2025Today8/30/2025Next Earnings (Estimated)10/30/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:MOLN CIK1745114 Webwww.molecularpartners.com Phone41-44-755-7700FaxN/AEmployees180Year FoundedN/APrice Target and Rating Average Price Target for Molecular Partners$12.00 High Price Target$12.00 Low Price Target$12.00 Potential Upside/Downside+213.7%Consensus RatingStrong Buy Rating Score (0-4)3.50 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)($2.08) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$61.39 million Net MarginsN/A Pretax Margin-9,548.41% Return on Equity-50.66% Return on Assets-45.13% Debt Debt-to-Equity RatioN/A Current Ratio9.35 Quick Ratio15.28 Sales & Book Value Annual Sales$681 thousand Price / Sales226.78 Cash FlowN/A Price / Cash FlowN/A Book Value$3.20 per share Price / Book1.20Miscellaneous Outstanding Shares40,375,000Free Float37,981,000Market Cap$154.43 million OptionableNot Optionable Beta1.10 These 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:MOLN) was last updated on 8/30/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredHow “Trump’s New Dollar” Could Impact Your WealthPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredMy NEXT $1 Trillion PredictionJames Altucher is making his next trillion-dollar prediction — and this time, it’s not Apple. He believes Elon...Paradigm Press | SponsoredTrump’s national nightmare is hereAI is no longer just about chatbots — it’s becoming the backbone of the global economy. While U.S. firms push ...Porter & Company | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Molecular Partners AG Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Molecular Partners With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.